Comparison of Visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer

British Journal of Cancer

Volumn 106, Issue 2, 2012, Pages 383-388

  Mohammed, Z M A ^a   McMillan, D C ^a   Elsberger, B ^a   Going, J J ^a   Orange, C ^a   Mallon, E ^a   Doughty, J C ^b   Edwards, J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

automated counting method; primary invasive breast cancer; survival; visual counting method

Indexed keywords

KI 67 ANTIGEN; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INVASION; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR GROWTH;

AUTOMATION; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM INVASIVENESS; TREATMENT OUTCOME; VISION, OCULAR;

EID: 84856432316     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.569     Document Type: Article

References (22)

1. Al Murri AM, Hilmy M, Bell J, Wilson C, McNicol A, Lannigan A, Doughty JC, McMillan DC (2008) The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. Br J Cancer 99: 1013-1019
2. Cancerstats (2008) http://info.cancerresearchuk.org/cancerstats/types/ breast/incidence. Accessed 25 June 2010
3. Canna K, Hilmy M, McMillan DC, Smith GW, McKee RF, McArdle CS, McNicol A (2008) The relationship between tumour proliferative activity, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Colorectal Dis 10: 663-667
4. de Azambuja E, Cardoso F, de Castro GJ, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96: 1504-1513 (Pubitemid 46762956)
5. Dowsett M, A'hern R, Salter J, Zabaglo L, Smith IE (2009) Who would have thought a single Ki67 measurement would predict long-term outcome? Breast Cancer Res 11(Suppl 3): S15
6. Dowsett M, Nielsen TO, A'hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF (2011) Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 103(22): 1656-1664
7. Faratian D, Kay C, Robson T, Campbell FM, Grant M, Rea D, Bartlett JMS (2009) Automated image analysis for high-throughput quantitative detection of er and pr expression levels in large-scale clinical studies: the team trial experience. Histopathology 55: 587-593
8. Fasanella S, Leonardi E, Cantaloni C, Eccher C, Bazzanella I, Aldovini D, Bragantini E, Morelli L, Cuorvo LV, Ferro A, Gasperetti F, Berlanda G, Dalla Palma P, Barbareschi M (2011) Proliferative activity in human breast cancer: ki-67 automated evaluation and the influence of different ki-67 equivalent antibodies. Diagn Pathol 6(Suppl 1): S7
9. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 966-978
10. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn H (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18: 1133-1144 (Pubitemid 47244357)
11. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M (2010) Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 119: 315-323
12. Jung S, Han W, Lee JW, Ko E, Kim E, Yu J, Moon H, Park IA, Oh D, Im S, Kim T, Hwang K, Kim S, Noh D (2009) Ki-67 expression gives additional prognostic information on st. gallen 2007 and adjuvant! Online risk categories in early breast cancer. Ann Surg Oncol 16: 1112-1121
13. Konsti J, Lundin M, Joensuu H, Lehtimäki T, Sihto H, Holli K, Turpeenniemi-Hujanen T, Kataja V, Sailas L, Isola J, Lundin J (2011) Development and evaluation of a virtual microscopy application for automated assessment of ki-67 expression in breast cancer. BMC Clin Pathol 11: 3
14. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33: 159-174 (Pubitemid 8054849)
15. McCormick D, Chong H, Hobbs C, Datta C, Hall PA (1993) Detection of the ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody mib1. Histopathology 22: 355-360 (Pubitemid 23159796)
16. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: globocan 2000. Int J Cancer 94: 153-156 (Pubitemid 32911406)
17. Scott RJ, Hall PA, Haldane JS, van Noorden S, Price Y, Lane DP, Wright NA (1991) A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol 165: 173-178
18. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P (2008) Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 17(4): 323-334
19. Tovey SM, Dunne B, Witton CJ, Cooke TG, Bartlett JMS (2006) Her4 in breast cancer: comparison of antibodies against intra-and extra-cellular domains of her4. Breast Cancer Res 8: R19
20. Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23(28): 7212-7220
21. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A (2008) Prognostic and predictive value of centrally reviewed ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from breast international group trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26: 5569-5575
22. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11: 174-183